Dr. Robin L. Jones on Eribulin Versus Dacarbazine in Patients With Leiomyosarcoma and Adipocytic Sarcoma
Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
This randomized phase III trial analyzed patients with unresectable metastatic liposarcoma or leiomyosarcoma who had previously received at least two lines of chemotherapy. The primary endpoint was overall survival (OS).
In the trial, eribulin demonstrated significant benefit for patients: OS was 13.5 months compared with 11.5 months with dacarbazine.
Jones points out that this trial is significant because OS benefit is seldom seen soft tissue sarcoma studies.
NIAGARA Trial Results Show Durvalumab/Chemo Improves EFS, OS in Cisplatin-Eligible MIBC
September 15th 2024In the NIAGARA trial, significant event-free survival and overall survival gains were observed with neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab in cisplatin-eligible bladder cancer.
Read More
T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2-Low/Ultralow MBC
September 15th 2024Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.
Read More
CheckMate 77T Trial of Perioperative Nivolumab Generates EFS Benefit in Resectable NSCLC
September 15th 2024In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.
Read More
